<i id='6C7988E902'><strike id='6C7988E902'><tt id='6C7988E902'><pre id='6C7988E902'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Trump demands the U.S. pay no more for drugs than other countries … again 
FDA approves Moderna’s RSV vaccine, its second licensed product 
Psychedelics group wrestles with new pharma identity 
Scientists uncover potential path to treating deadly childhood tumor 
After affirmative action ruling, medical educators look to 'holistic review' 
Scientific mystery highlights the blind spots in genomics databases
Psychedelics group wrestles with new pharma identity 
Elevance PBM president out as customers face prescription chaos 
In age of alternative facts, a scholarly course on calling out crap 
Stopping antidepressants leads to symptoms for 1 in 6 patients 
Moonlake's readout produced a cash windfall. Risks remain 
Medicare Advantage's lean provider networks lead CMS complaints 
Dobbs anniversary: the lost opportunity of abortion as health care 
Hundreds died while taking an arthritis drug, but nobody alerted patients 
How one medical school became remarkably diverse 
